809272-64-8
809272-64-8
Chemical Structure
PTP1B-IN-3
- CAS No.: 809272-64-8
- Formula:C12H7BrF2NO3P
- Molecular Weight:362.06
IUPAC Name: ((3-bromo-7-cyanonaphthalen-2-yl)difluoromethyl)phosphonic acid
InChIKey: BWJOQFMMTKEZGA-UHFFFAOYSA-N
SMILES: BrC1=C(C(F)(P(O)(O)=O)F)C=C2C(C=CC(C#N)=C2)=C1
Biological Activity: PTP1B-IN-3 is a potent and orally active PTP1B inhibitor with IC50s of 120 nM for both PTP1B and TCPTP. PTP1B-IN-3 has antidiabetic and anticancer effects[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PTP1B-IN-3 | 99.69% | PTP1B-IN-3 is a potent and orally active PTP1B inhibitor with IC50s of 120 nM for both PTP1B and TCPTP. PTP1B-IN-3 has antidiabetic and anticancer effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HNMPA | 99.89% | HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BRD9876 | 99.37% | BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CAY 10465 | 98.75% | CAY 10465 is a selective and high-affinity AhR agonist, with a Ki of 0.2 nM, and shows no effect on estrogen receptor (Ki >100000 nM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PTP1B-IN-3 diammonium | ≥95.0% | PTP1B-IN-3 diammonium is a potent and orally active PTP1B inhibitor with IC50s of 120 nM for both PTP1B and TCPTP. PTP1B-IN-3 diammonium has antidiabetic and anticancer effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4-(4-Bromo-3-(hydroxymethyl)phenoxy)benzonitrile (Standard) | ≥98% | 4-(4-Bromo-3-(hydroxymethyl)phenoxy)benzonitrile (Standard) is the analytical standard of 4-(4-Bromo-3-(hydroxymethyl)phenoxy)benzonitrile. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CDC14A/B-IN-2 | CDC14A/B-IN-2, phosphotyrosine mimetic, is a competitive human CDC14A/B phosphatase inhibitor with IC50 values of 10.4 and 11.2 μM, and Ki values of 5.8 and 7.3 μM. CDC14A/B-IN-2 shows at least 20-fold selectivity over other protein tyrosine phosphatases. CDC14A/B-IN-2 can be used for the research of cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naphthalene-2,6-dicarboxylic acid | 99.93% | Naphthalene-2,6-dicarboxylic acid (Naphthalene-2,6-dicarboxylate) is a metal-organic framework (MOF). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2,6-Anthracene dicarboxylic acid | 2,6-Anthracene dicarboxylic acid (Anthracene-2,6-dicarboxylic acid) is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naphthalene-2,7-dicarboxylic acid | Naphthalene-2,7-dicarboxylic acid (2,7-Naphthalenedicarboxylic acid) is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
([1,1'-Biphenyl]-4,4'-diylbis(methylene))bis(phosphonic acid) | ([1,1'-Biphenyl]-4,4'-diylbis(methylene))bis(phosphonic acid) (Toluene,p,p'-methylenedi) is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yongxin Han, et al. Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3200-5. [Content Brief]
- [2]. Patel D, .Discovery of orally active, potent, and selective benzotriazole-based PTP1B inhibitors. ChemMedChem. 2011 Jun 6; 6(6):1011-6. [Content Brief]
